Download Files:
CDK9-IN-7
$630 – $2,800
Products Details
Product Description
– CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC[1].
Web ID
– HY-126251
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C29H37N7O2S
References
– [1]Wang X, et al. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Jul 25;181:111535.
CAS Number
– 2369981-71-3
Molecular Weight
– 547.71
Compound Purity
– 98.05
SMILES
– O=C(N(C)C)C1=CC2=CN=C(NC3=CC=C(NC(CCCCCCCN=C=S)=O)C=C3)N=C2N1C4CCCC4
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 62.5 mg/mL (ultrasonic)
Target
– Apoptosis;CDK
Isoform
– CDK4;CDK6;CDK9
Pathway
– Apoptosis;Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
